Adaptive Neuro Care System

Project Information

Neuro Care System

Grant agreement ID: 728813

DOI

10.3030/728813

Project closed

EC signature date 24 July 2016

Start date 1 August 2016

End date 31 October 2016

Funded under

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

SMART-HEART FEJLESZTESI ES TANACSADO KORLATOLT FELELOSSEGY TARSASAG
Hungary

Periodic Reporting for period 1 - Neuro Care System (Adaptive Neuro Care System)

Reporting period: 2016-08-01 to 2016-10-31

Summary of the context and overall objectives of the project

The innovation project sets the target building Neuro Care which is a medical monitoring system of Parkinson’s disease (PD) and associated neurological diseases. Neuro Care is able to assess the effectiveness of prescribed drugs, and supporting the therapy treatments on mobile information-technology-base.
It is possible to live for decades with neuro-psychiatric disorders, while patients and caregivers are out of work. Pharmaceutical treatments and health care institutions are extremely expensive, although an alternative has emerged during the past decades in the form of deep brain stimulation (DBS) procedures. The early detection of the typical symptoms is crucial, as early treatment may prolong patient’s good life quality, maintain the ability to work, and minimize the burden on individual caregivers and society as a whole to the greatest extent possible.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During project phase 1 we examined the innovation and business opportunities of the new technology in detail:
We have studied the market potential of the new technology. Within this study, the potential, the DACH region and the US markets have been examined. TAM, SAM and SOM markets size have been determined. In order to assess the technological advantages detailed competitor analysis was performed. Moreover, medical professional and patient acceptance of the new technology has been assessed through interviews.
We developed the business plan related to the implementation of our technology. We assessed the business and other risks. We developed the NeuroCare products pricing strategies, market introduction schedule and the strategy for IP. In addition, we designed the financing plan for innovation.
We analyzed and evaluated the performance of the diagnostic system of the new technology. In addition, we detailed the specification of the technology components based on the test results. We determined components and costs necessary for mass production.
We designed the work plan of project phase 2 and the relating work packages. Composition and size of human resources have been determined, as well as the order and schedule of deliverables and milestones.
We designed the technology validation plan. The synopsis and schedule of pre-clinical and clinical studies have been determined, as well as the technology standard qualification tests.
Also data protection tasks related to the innovation and future products have been examined. In addition, we developed the IP and knowledge management strategy

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

It is possible to live for decades with neuro-psychiatric disorders, while patients and caregivers are out of work. Pharmaceutical treatments and health care institutions are extremely expensive, although an alternative has emerged during the past decades in the form of deep brain stimulation (DBS) procedures. The early detection of the typical symptoms is crucial, as early treatment may prolong patient’s good life quality, maintain the ability to work, and minimise the burden on individual caregivers and society as a whole to the greatest extent possible.
The basic symptoms of PD are movement-related (motoric): slowness of movement, rigidity, shaking, occasionally coupled with non-motoric symptoms like sleep disorder, psychiatric and vegetative signs. The (cause of the) disease cannot be cured, its symptomatic treatment typically involves taking pharmaceutics regularly 3-6 times a day. The aim of the therapy is to prolong the periods with good movement status, to reduce the severity of symptoms, and reduce the frequency and duration of conditions with involuntary writhing or hypokinesia.
Essential tremor and dystonia are also further application fields for this innovation but Parkinson disease will be the first area where Neuro Care starts

NeuroCare System